intrommune_icon_500x500.png
Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory
June 01, 2022 13:33 ET | Intrommune Therapeutics
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
Allergy Immunotherapy Market
Worldwide Allergy Immunotherapy Industry to 2028 - Increasing Approval of Allergy Immunotherapy by Regulatory Authorities are Driving Growth
April 28, 2022 07:23 ET | Research and Markets
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapy Market, by Treatment Type, by Allergy Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity...
Global Meal Kit Delivery Services Market
Outlook on the Meal Kit Delivery Services Global Market to 2030: Online Segment Accounted for the Largest Revenue Share of More Than 63.2% in 2021
April 21, 2022 06:43 ET | Research and Markets
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Meal Kit Delivery Services Market Size, Share & Trends Analysis Report by Offering (Heat & Eat, Cook & Eat), by Service (Single,...
intrommune_icon_500x500.png
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
April 06, 2022 08:30 ET | Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Elijah's Law Report
New Report Finds Major Gaps in Child Care Policies for Food Allergy Nationwide
February 25, 2022 06:50 ET | Asthma and Allergy Foundation of America
Washington, D.C., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Today, the Asthma and Allergy Foundation of America (AAFA) and the Elijah-Alavi Foundation (EAF) released “Child Care Policies for Food Allergy:...
intrommune_icon_500x500.png
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
February 08, 2022 08:30 ET | Intrommune Therapeutics
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing in Fully Enrolled Cohort 2 Intrommune Launches Series B Financing NEW YORK, Feb. 08, 2022 (GLOBE...
22157.jpg
Allergy Immunoassay Market Brief: Sophistication in Testing is Leading to More Automated Effective Testing
January 25, 2022 05:23 ET | Research and Markets
Dublin, Jan. 25, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunoassay Brief" report has been added to ResearchAndMarkets.com's offering. Allergies are a number of conditions that are caused by...
intrommune_icon_500x500.png
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
December 21, 2021 09:39 ET | Intrommune Therapeutics
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
AllerSmart IgE
AllerSmart IgE Allergy Testing Now Available for At-Home or At-Clinic and Includes the 9 'Big Foods' and 29 Key Environmentals
November 26, 2021 09:00 ET | AllerSmart IgE
VICTORIA, British Columbia, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Covid 19 has dramatically impacted the healthcare industry and as such, antibody diagnostics have quickly evolved and gained...
intrommune_icon_500x500.png
Intrommune Participates in the Forsyth dentech 2021 Conference
September 22, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...